Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 84 for your search:
At Hospital/Institution:
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
Phase:
Phase IV
Type:
Natural history/Epidemiology, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
U2963n
, NCT00097565
2.
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
Phase:
Phase IV
Type:
Supportive care
Status:
Active
Age:
19 and over
Sponsor:
NIMH
Protocol IDs:
R01 MH079420
, DAHBR 96-BHC, NCT00536172
3.
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLBH589B2212
, NCT00490776
4.
Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CAN-NCIC-MA17
, CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
5.
Phase III Randomized Study of Adjuvant Isotretinoin With or Without Monoclonal Antibody Ch14.18, Interleukin-2, and Sargramostim (GM-CSF) in Patients With Neuroblastoma Who Have Completed Myeloablative Therapy and Autologous Stem Cell Transplantation (Arm I Closed to Accrual as of 4/16/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
30 and under at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ANBL0032
, ANBL0032, COG-P9842, NCT00026312
6.
Phase III Randomized Study of Adjuvant Cyclophosphamide and Doxorubicin Versus Single-Agent Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-40101
, NCT00041119
7.
Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NSABP-R-04
, NCT00058474, CALGB-NSABP-R-04
8.
Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-25-02
, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28
9.
Phase III Study of Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiotherapy in Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI
Protocol IDs:
COG-ARST0331
, NCT00075582, ARST0331
10.
Phase III Randomized Study of Dexamethasone Versus Prednisone During Induction and High-Dose Methotrexate With Leucovorin Rescue Versus Escalating-Dose Methotrexate Without Leucovorin Rescue During Interim Maintenance I in Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
1 to under 31
Sponsor:
NCI
Protocol IDs:
COG-AALL0232
, NCT00075725, AALL0232
11.
Phase III Randomized Study of Zoledronate for the Prevention of Skeletal-Related Events in Patients With Prostate Cancer and Bone Metastases Undergoing Androgen Deprivation Therapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-90202
, ECOG-CALGB-90202, NCT00079001, SWOG-CALGB-90202, CAN-NCIC-PRC2
12.
Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCCTG-N0147
, ECOG-N0147, N0147, NCT00079274
13.
Phase III Randomized Adjuvant Study of Standard-Dose Versus Reduced-Dose Craniospinal Radiotherapy and Posterior Fossa Boost Versus Tumor Bed Boost Radiotherapy in Combination With Chemotherapy Comprising Vincristine, Cisplatin, Lomustine, and Cyclophosphamide in Pediatric Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ACNS0331
, ACNS0331, NCT00085735
14.
Phase III Randomized Study of Different Combination Chemotherapy Regimens in Pediatric Patients With Newly Diagnosed Standard-Risk B-Precursor Acute Lymphoblastic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
1 to under 10
Sponsor:
NCI
Protocol IDs:
COG-AALL0331
, AALL0331, NCT00103285
15.
Phase III Randomized Study of Neoadjuvant Induction Therapy Comprising Doxorubicin, Cisplatin, and High-Dose Methotrexate (MAP) Followed by Surgery and Adjuvant Maintenance Therapy Comprising MAP Alone Versus MAP and PEG-Interferon Alfa-2b OR MAP Combined With Ifosfamide and Etoposide in Patients With Resectable High-Grade Osteosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
5 to 40 at diagnostic biopsy
Sponsor:
NCI
Protocol IDs:
COG-AOST0331
, AOST0331, NCT00134030, ISRCTN67613327, EU-20530, MRC-EURAMOS1, MRC-BO08, EUDRACT-2004-000242-20
16.
Phase III Randomized Study of Docetaxel and Prednisone With Versus Without Atrasentan in Patients With Hormone-Refractory Stage IV Prostate Cancer and Bone Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0421
, S0421, NCT00134056
17.
Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer and at High Risk for Recurrence Based on Molecular Markers
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E5202
, E5202, NCT00217737
18.
Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Arm III [Cetuximab and Bevacizumab in Combination With FOLFOX or FOLFIRI] Closed to Accrual as of 09/10/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-C80405
, C80405, SWOG-C80405, NCT00265850
19.
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
ECOG-PACCT-1
, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
20.
Phase III Randomized Study of Adjuvant Sunitinib Malate Versus Sorafenib in Patients With Resected Renal Cell Carcinoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E2805
, E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
21.
Phase III Study of Risk-Based Therapy Comprising Observation Only, Adjuvant Radiotherapy, or Adjuvant Chemoradiotherapy or Neoadjuvant Chemoradiotherapy, Surgery, and Adjuvant Chemotherapy With or Without Radiotherapy in Young Patients With Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 30 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ARST0332
, ARST0332, NCT00346164
22.
Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 30
Sponsor:
NCI
Protocol IDs:
COG-AAML0531
, AAML0531, NCT00372593
23.
Phase III Study of Adjuvant Vincristine, Dactinomycin and Doxorubicin Hydrochloride With or Without Radiotherapy or Observation Only in Younger Patients Who are Undergoing Nephrectomy for Newly Diagnosed Stage I-III Favorable Histology Wilms' Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 30 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-AREN0532
, AREN0532, NCT00352534
24.
Phase III Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan Hydrochloride in Combination With Radiotherapy in Patients With Newly Diagnosed, Intermediate-Risk Rhabdomyosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI
Protocol IDs:
COG-ARST0531
, NCT00354835, ARST0531
25.
Phase III Study of Induction Therapy Comprising Cytarabine, Daunorubicin Hydrochloride, Thioguanine, and Asparaginase Followed by Intensification Therapy Comprising Cytarabine and Etoposide in Pediatric Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 4 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-AAML0431
, AAML0431, NCT00369317
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
